US Cannabis State GMP: The 2026 Baseline for a Multi-State Operator
In the absence of federal legalisation, US cannabis manufacturers operate under a patchwork of state rules that converge on a recognisable GMP baseline drawn from FOCUS (Foundation of Cannabis Unified Standards), ASTM Committee D37, AHPA cannabis standards, and increasingly from FDA 21 CFR 111 (dietary supplements) and 21 CFR 117 (food) as states harmonise with federal frameworks they cannot legally invoke directly. This guide walks the GMP elements every multi-state operator should already meet in 2026, the seed-to-sale traceability backbone, the testing and recall obligations, and a practical path to a programme that survives both routine state inspection and the federal regulator that arrives the day after federal rescheduling.
The state baseline and where FOCUS, ASTM and AHPA fit
Seed-to-sale, METRC and the genealogy obligation
Testing, COA reconciliation and the lab-shopping problem
Recall, complaint and adverse-event handling under state rule
A 60-day readiness path and the federal-rescheduling preparation
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Frequently asked
Does FDA already inspect cannabis facilities?
How do FOCUS, ASTM and AHPA differ?
Is METRC the only state track-and-trace system?
What happens to state rules if cannabis is federally rescheduled?
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
